I.Q Therapies Ltd 07041241 false 2024-03-01 2025-02-28 2025-02-28 The principal activity of the company is that of therapist services. Digita Accounts Production Advanced 6.30.9574.0 true 07041241 2024-03-01 2025-02-28 07041241 2025-02-28 07041241 bus:Director2 1 2025-02-28 07041241 bus:OrdinaryShareClass1 bus:CumulativeShares 2025-02-28 07041241 core:CurrentFinancialInstruments 2025-02-28 07041241 core:CurrentFinancialInstruments core:WithinOneYear 2025-02-28 07041241 core:Non-currentFinancialInstruments core:AfterOneYear 2025-02-28 07041241 core:FurnitureFittingsToolsEquipment 2025-02-28 07041241 core:OtherPropertyPlantEquipment 2025-02-28 07041241 bus:SmallEntities 2024-03-01 2025-02-28 07041241 bus:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 07041241 bus:FilletedAccounts 2024-03-01 2025-02-28 07041241 bus:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 07041241 bus:Director2 2024-03-01 2025-02-28 07041241 bus:Director2 1 2024-03-01 2025-02-28 07041241 bus:HighestPaidDirector 2024-03-01 2025-02-28 07041241 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-03-01 2025-02-28 07041241 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 07041241 core:Goodwill 2024-03-01 2025-02-28 07041241 core:FurnitureFittings 2024-03-01 2025-02-28 07041241 core:FurnitureFittingsToolsEquipment 2024-03-01 2025-02-28 07041241 core:OfficeEquipment 2024-03-01 2025-02-28 07041241 core:OtherPropertyPlantEquipment 2024-03-01 2025-02-28 07041241 core:PlantMachinery 2024-03-01 2025-02-28 07041241 countries:EnglandWales 2024-03-01 2025-02-28 07041241 2024-02-29 07041241 bus:Director2 1 2024-02-29 07041241 core:FurnitureFittingsToolsEquipment 2024-02-29 07041241 core:OtherPropertyPlantEquipment 2024-02-29 07041241 2023-03-01 2024-02-29 07041241 2024-02-29 07041241 bus:Director2 1 2024-02-29 07041241 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-02-29 07041241 core:CurrentFinancialInstruments 2024-02-29 07041241 core:CurrentFinancialInstruments core:WithinOneYear 2024-02-29 07041241 core:Non-currentFinancialInstruments core:AfterOneYear 2024-02-29 07041241 core:FurnitureFittingsToolsEquipment 2024-02-29 07041241 core:OtherPropertyPlantEquipment 2024-02-29 07041241 bus:Director2 1 2023-03-01 2024-02-29 07041241 bus:HighestPaidDirector 2023-03-01 2024-02-29 07041241 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-03-01 2024-02-29 07041241 bus:Director2 1 2023-02-28 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07041241

I.Q Therapies Ltd
Unaudited Filleted Abridged Financial Statements
for the Year Ended 28 February 2025

I.Q Therapies Ltd

Contents

Abridged Balance Sheet | 1 to 2
Notes to the Unaudited Abridged Financial Statements | 3 to 9

I.Q Therapies Ltd

(Registration number: 07041241)
Abridged Balance Sheet as at 28 February 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Intangible assets | 3 | 11,815 | 12,603
Tangible assets | 4 | 7,743 | 7,811
|  | 19,558 | 20,414
Current assets |  |  |
Debtors |  | 24,273 | 33,056
Cash at bank and in hand |  | 34,801 | 17,305
|  | 59,074 | 50,361
Prepayments and accrued income |  | 2,326 | 2,294
Creditors: Amounts falling due within one year |  | (10,647) | (15,155)
Net current assets |  | 50,753 | 37,500
Total assets less current liabilities |  | 70,311 | 57,914
Creditors: Amounts falling due after more than one year |  | (3,833) | (5,833)
Provisions for liabilities |  | (114) | (743)
Accruals and deferred income |  | (1,162) | (2,933)
Net assets |  | 65,202 | 48,405
Capital and reserves |  |  |
Called up share capital | 5 | 2 | 2
Retained earnings |  | 65,200 | 48,403
Shareholders' funds |  | 65,202 | 48,405

For the financial year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

I.Q Therapies Ltd

(Registration number: 07041241)
Abridged Balance Sheet as at 28 February 2025

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 19 November 2025

......................................... Mrs Sally Louise McDonald Abel Director

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

1 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 20% Reducing balance method
Fixtures and fittings | 20% Reducing balance method
Office equipment | 20% Reducing balance method

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class | Amortisation method and rate
Goodwill | 4% Straight line basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

2 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 2 (2024 - 2).

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

3 | Intangible assets

| Total £
Cost or valuation
At 1 March 2024 | 19,692
At 28 February 2025 | 19,692
Amortisation
At 1 March 2024 | 7,089
Amortisation charge | 788
At 28 February 2025 | 7,877
Carrying amount
At 28 February 2025 | 11,815
At 29 February 2024 | 12,603

4 | Tangible assets

| Furniture, fittings and equipment £ | Other tangible assets £ | Total £
Cost or valuation
At 1 March 2024 | 13,849 | 2,727 | 16,576
Additions | - | 1,866 | 1,866
At 28 February 2025 | 13,849 | 4,593 | 18,442
Depreciation
At 1 March 2024 | 7,273 | 1,492 | 8,765
Charge for the year | 1,314 | 620 | 1,934
At 28 February 2025 | 8,587 | 2,112 | 10,699
Carrying amount
At 28 February 2025 | 5,262 | 2,481 | 7,743
At 29 February 2024 | 6,576 | 1,235 | 7,811

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

5 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary shares of £1 each | 2 | 2 | 2 | 2

6 | Dividends

Interim dividends paid

|  | 2025 £ |  | 2024 £
Interim dividend of £2,300.00 (2024 - £Nil) per each Ordinary shares |  | 4,600 |  | -

Interim dividends paid

|  | 2025 £ |  | 2024 £
Interim dividend of £2,300 (2024 - £Nil) per each Ordinary shares |  | 4,600 |  | -

7 | Related party transactions

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

Transactions with the director

2025 | At 1 March 2024 £ | Advances to director £ | Other payments made to company by director £ | At 28 February 2025 £
Mrs Sally Louise McDonald Abel
Directors loan | (7,281) | 40,685 | (33,452) | (48)

2024 | At 1 March 2023 £ | Advances to director £ | Other payments made to company by director £ | At 29 February 2024 £
Mrs Sally Louise McDonald Abel
Directors loan | (10,045) | 31,761 | (28,997) | (7,281)

I.Q Therapies Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 28 February 2025

Director's remuneration

The director's remuneration for the year was as follows:

| 2025 £ | 2024 £
Remuneration | 33,671 | 34,821
Contributions paid to money purchase schemes | 1,010 | 1,044
| 34,681 | 35,865

In respect of the highest paid director:

| 2025 £ | 2024 £
Remuneration | 33,671 | 34,821